ATE263781T1 - Neurotrophischer al-1 faktor, einer ligand verwant mit dem eph tyrosine kinase receptor - Google Patents

Neurotrophischer al-1 faktor, einer ligand verwant mit dem eph tyrosine kinase receptor

Info

Publication number
ATE263781T1
ATE263781T1 AT95942838T AT95942838T ATE263781T1 AT E263781 T1 ATE263781 T1 AT E263781T1 AT 95942838 T AT95942838 T AT 95942838T AT 95942838 T AT95942838 T AT 95942838T AT E263781 T1 ATE263781 T1 AT E263781T1
Authority
AT
Austria
Prior art keywords
neurotrophic
factor
tyrosine kinase
kinase receptor
ligand related
Prior art date
Application number
AT95942838T
Other languages
English (en)
Inventor
Ingrid W Caras
John W Winslow
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/486,449 external-priority patent/US6280732B1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE263781T1 publication Critical patent/ATE263781T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95942838T 1994-10-27 1995-10-26 Neurotrophischer al-1 faktor, einer ligand verwant mit dem eph tyrosine kinase receptor ATE263781T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33012894A 1994-10-27 1994-10-27
US08/486,449 US6280732B1 (en) 1994-10-27 1995-06-07 Methods of using an AL-1 neurotrophic factor immunoadhesin
PCT/US1995/014016 WO1996013518A1 (en) 1994-10-27 1995-10-26 Al-1 neurotrophic factor, a ligand for an eph-related tyrosine kinase receptor

Publications (1)

Publication Number Publication Date
ATE263781T1 true ATE263781T1 (de) 2004-04-15

Family

ID=26987135

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95942838T ATE263781T1 (de) 1994-10-27 1995-10-26 Neurotrophischer al-1 faktor, einer ligand verwant mit dem eph tyrosine kinase receptor

Country Status (7)

Country Link
EP (1) EP0787148B1 (de)
AT (1) ATE263781T1 (de)
AU (1) AU716924B2 (de)
CA (1) CA2203888C (de)
DE (1) DE69532857T2 (de)
IL (1) IL115792A (de)
WO (1) WO1996013518A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2240981T3 (es) * 1994-12-06 2005-10-16 Immunex Corporation Citocina denominada lerk-7.
US6057124A (en) * 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
AUPP674898A0 (en) * 1998-10-27 1998-11-19 Walter And Eliza Hall Institute Of Medical Research, The A method of treatment
AU2001280566A1 (en) * 2000-07-14 2002-01-30 Children's Medical Center Corporation A trophic factor capable of producing a neurosalutary effect in a subject
WO2002051438A2 (en) * 2000-12-22 2002-07-04 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Use of repulsive guidance molecule (rgm) and its modulators
WO2003004057A1 (en) * 2001-07-03 2003-01-16 The Hospital For Sick Children Ephrin and eph receptor mediated immune modulation
JP2005512528A (ja) * 2001-12-10 2005-05-12 ミレニアム・ファーマシューティカルズ・インコーポレイテッド １４１９、５８７６５および２２１０を用いて心血管疾患を処置するための方法および組成物
EP1553963A4 (de) 2002-09-24 2006-05-03 Burnham Inst NEUE MITTEL ZUR MODULIERUNG DER EPH-REZEPTOR-AKTIVITûT
US7862816B2 (en) 2003-03-12 2011-01-04 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
CA2522680A1 (en) 2003-04-15 2004-10-28 Xenon Pharmaceuticals Inc. Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof
EP1730196B1 (de) 2004-03-12 2010-12-22 Vasgene Therapeutics, Inc. Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
KR20120123619A (ko) 2004-03-12 2012-11-08 바스진 테라퓨틱스, 인크. 혈관형성 및 종양 성장을 억제하기 위한 폴리펩티드 화합물
CA2581423A1 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
CN101146822A (zh) 2005-01-27 2008-03-19 伯纳姆研究所 EphB受体结合肽
CA2624562A1 (en) 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
JP5749009B2 (ja) 2007-08-13 2015-07-15 バスジーン セラピューティクス，インコーポレイテッドＶａｓｇｅｎｅｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ＥｐｈＢ４に結合するヒト化抗体を利用する癌治療剤
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
WO2011070045A1 (en) 2009-12-08 2011-06-16 Abbott Gmbh & Co. Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
NZ714482A (en) 2012-01-27 2017-08-25 Abbvie Inc Composition and method for diagnosis and treatment of diseases associated with neurite degeneration

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU685765B2 (en) * 1992-11-13 1998-01-29 Amgen, Inc. (Eck) receptor ligands
WO1994011384A1 (en) * 1992-11-13 1994-05-26 Immunex Corporation Novel cytokine designated elk ligand
ATE232901T1 (de) * 1994-04-04 2003-03-15 Regeneron Pharma Biologisch aktive ligande der eph familie

Also Published As

Publication number Publication date
AU716924B2 (en) 2000-03-09
CA2203888A1 (en) 1996-05-09
IL115792A (en) 2007-06-17
IL115792A0 (en) 1996-01-19
DE69532857D1 (de) 2004-05-13
WO1996013518A1 (en) 1996-05-09
EP0787148B1 (de) 2004-04-07
DE69532857T2 (de) 2005-04-28
AU4405396A (en) 1996-05-23
CA2203888C (en) 2011-08-23
EP0787148A1 (de) 1997-08-06

Similar Documents

Publication Publication Date Title
ATE263781T1 (de) Neurotrophischer al-1 faktor, einer ligand verwant mit dem eph tyrosine kinase receptor
ATE522609T1 (de) Neurotrophe faktoren
DK0397633T3 (da) Fibronectinbindende protein samt fremstilling deraf
DE68916285D1 (de) Verfahren zur Dampfreformierung von Kohlenwasserstoffen.
DE69804015D1 (de) Hydrocrack-verfahren mit mittendestillat-selektivität
DE69008098D1 (de) Verfahren und Einrichtung zur Herstellung von Federkernkonstruktionen für Matratzen, Kissen o.dgl.
IL191078A0 (en) POLYPEPTIDES WHICH BIND TO ErbB3 OR ErbB4 RECEPTOR PROTEIN TYROSINE KINASE OR BOTH, NUCLEIC ACIDS, VECTORS, HOST CELLS, COMPOSITIONS, METHOD FOR PRODUCTION AND USE OF SUCH POLYPEPTIDES
DE68903482D1 (de) Zement, verfahren zur herstellung dieses zements und verfahren zur herstellung von produkten mit diesem zement.
DE69517725D1 (de) Gerät zur Vermeidung von Flugzeugkollisionen, insbesondere mit dem Boden durch Anflugneigungskontrolle
DE3879147D1 (de) Verfahren zur dampfdehydrierung von dehydrierbaren kohlenwasserstoffen unter gleichzeitiger oxydativer wiedererwaermung.
CA2002868A1 (en) Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3864585D1 (de) Dns-molekule, codierend fuer non-a-non-b-hepatitis-antigene und ihre verwendung zur herstellung dieser antigene.
DE3785633D1 (de) Molekuele mit bindungsstellen von antikoerpern, die katalytische eigenschaften besitzen.
WO1997021811A3 (en) Novel tyrosine kinase receptors and ligands
DE3777421D1 (de) Hochfester stahl fuer ventilfedern, verfahren zur herstellung des stahles und daraus hergestellte ventilfedern.
DE69016112D1 (de) Stabilisatormischung zur Verwendung in halogenhaltigen Harzen.
DE59005310D1 (de) Mit flüssigem Brennstoff betriebenes Heizgerät.
EP0854185A3 (de) Rezeptor-Proteine zu Bestimmungszwecke und Liganden
ATE91520T1 (de) Nassgelegte bahn, verwendbar als beschichtungsunterlage.
ES2072868T3 (es) Proteina capaz de unir la fibronectina y su preparacion.
DE3576361D1 (de) Rekombinante dna, damit transformierter mikroorganismus, und verfahren zur herstellung von menschlicher cu-zn superoxiddismutase unter verwendung des transformierten mikroorganismus.
DE69007776D1 (de) Verfahren zur Herstellung sulfonierter Dispergiermittel aus Erdölasphaltfraktionen.
IT8620548A0 (it) Procedimento e dispositivo per la fabbricazione di prodotti in fibra di vetro, per esempio veli, feltri, filati e stoppini.
DE58900532D1 (de) Verfahren zur herstellung von bifunktionellen anionenaustauschharzen, neue bifunktionelle anionenaustauschharze und ihre verwendung.
DE58902421D1 (de) Verfahren zur herstellung von ethylen/vinylacetat-copolymerisaten mit erhoehter festigkeit, neue ethylen/vinylacetat-copolymerisate und ihre verwendung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0787148

Country of ref document: EP